1652 — Fusen Pharmaceutical Co Cashflow Statement
0.000.00%
Last trade - 00:00
- HK$749.96m
- HK$1.13bn
- CNY565.61m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 63.8 | 78.4 | 23.8 | -31 | -29.4 |
Depreciation | |||||
Non-Cash Items | 3.97 | 26 | 40.2 | 65.6 | 71.6 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -68.6 | 26.4 | -40 | 41.7 | -151 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 20.4 | 153 | 47.8 | 110 | -73.3 |
Capital Expenditures | -200 | -58.6 | -110 | -29.6 | -105 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -61 | -9.55 | -173 | 16.4 | -2.85 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -261 | -68.2 | -283 | -13.1 | -108 |
Financing Cash Flow Items | -0.073 | -9.27 | -0.192 | -17.2 | -12.6 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 5.45 | -116 | 20.5 | -51.8 | 88.5 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -230 | -34 | -216 | 47 | -93.3 |